BioNTech Navigates Tumultuous Waters: From Vaccine Triumph to Pioneering Cancer Research
BioNTech experiences a significant decline in financial performance, with earnings per share dropping from €1.90 to €1.08. Revenue decreases from €1.479 billion to €1.19 billion but still surpasses market expectations.…